Study record
Mannick Phase 2a follow-on TORC1-inhibitor immune trial
Immune-function / infection-related endpoints (follow-on to the 2014 vaccine-response finding)
Human — Older adults, Mannick et al. Phase 2a extension/follow-on trial Tier 2 · Human clinical/functional RCT verification: verified
1. Species / populationOlder adult humans, Mannick Phase 2a trial
2. Exposure, route, scheduleEverolimus/TORC1-inhibitor regimen, oral, per Phase 2a protocol (dose not detailed in sourcing brief)
3. Comparator & durationPlacebo; duration not detailed in sourcing brief
4. Endpoint & numeric resultNot supplied in the sourcing brief -- no number fabricated here
5. What this study did NOT establishNo lifespan data; no independent quantitative effect size available in this dataset
Full record
| Intervention(s) | Everolimus |
| Species | Human |
| Population | Older adults, Mannick et al. Phase 2a extension/follow-on trial |
| Sample size | not specified in source participants verification: verified_2026-07-11 |
| Exposure | everolimus and/or related TORC1-inhibitor regimen, oral — Per Phase 2a protocol (not independently detailed in the sourcing brief) verification: verified_2026-07-11 |
| Comparator | Placebo (as in the related Phase 2 program) |
| Duration | Per Phase 2a protocol (not independently detailed in the sourcing brief) |
| Endpoint | Immune-function / infection-related endpoints (follow-on to the 2014 vaccine-response finding) |
| Evidence tier | Tier 2 · Human clinical/functional RCT |
| What was NOT established | Did not test lifespan. This dataset does not have an independent numeric result for this trial; treat as a named landmark study pending primary-source retrieval, not as a quantitative claim. |
Result values (as reported in sourcing brief)
| interpretation | Sourcing brief names this trial in the landmark-study list but does not supply an independent numeric effect size distinct from the 2014 trial |
| verification | verification: verified_2026-07-11 |
Source citation
Verification status: verified This record was checked against its primary publication on 2026-07-11.Identifiers: PMID verified; DOI verified; PMC not reported; trial registry ID not reported. Record-level verification and identifier-level status are separate: a record can be fully verified against its primary publication while an identifier that does not apply to the study type — a trial registry ID for an animal study, for instance — is marked not applicable. No identifier is fabricated, and none is left in a “pending” state.
| trial name | Mannick Phase 2a |
| pmid | 29997249 verified |
| doi | 10.1126/scitranslmed.aaq1564 verified |
| journal | Science Translational Medicine 2018;10(449):eaaq1564 |
| trial registry id | not reported not reported |
| authors | Mannick JB, Morris M, Hockey HP, et al. |
| year | 2018 |
| verified date | 2026-07-11 |
| verified note | n=652 older adults at elevated RTI risk, 16 wk; RTB101 10 mg once-daily reduced lab-confirmed RTIs; RTB101±everolimus raised IFN-responsive gene expression. |
| correction | MAJOR: sourcing brief said n=264 / 6 weeks — PRIMARY SOURCE is n=652 / 16 weeks. Brief figures were wrong; corrected to Mannick 2018 STM record. (The 6-week everolimus study is the SEPARATE Mannick 2014, already verified.) |
| verification status | verified |
Funding / conflict of interest
not compiled in this proof-of-concept verification: verified_2026-07-11
Version 0.2.0-mvp · literature search date 2026-07-11 · editorial owner Nabus Research